6 months, 1 week ago
The FDA approves a new type of schizophrenia drug
The FDA approves a new type of schizophrenia drug The Food and Drug Administration, as expected, approved KarXT, the first new type of drug for schizophrenia in decades. AILSA CHANG, HOST: Today, the Food and Drug Administration approved the first new type of drug for schizophrenia in decades. LUPKIN: Since the first antipsychotic drug was introduced in the 1950s, the subsequent medications to treat psychosis act on the same chemical that helps the brain communicate with the rest of the body - dopamine. But for the first time, there's a new medicine for psychosis that does not act on dopamine and has had fewer side effects in clinical trials.


Discover Related

2 weeks, 5 days ago
From mines to minds: how lithium shapes energy and psychiatry

2 months, 3 weeks ago
Alzheimer’s Drugs Eyed by Investors Seeking Obesity-Like Gains

3 months, 2 weeks ago
The FDA restricts a psychoactive mushroom used in some edibles

4 months, 1 week ago
I'm a pharmacist... here's 4 common drugs I'm scared to prescribe

4 months, 1 week ago
Republicans and RFK Jr. have embraced psychedelics. What could go wrong?

4 months, 4 weeks ago
Massachusetts voters reject proposal to legalize certain psychedelic drugs

5 months, 1 week ago
FDA approves Cobenfy, a brand new type of schizophrenia drug : Short Wave : NPR

6 months, 2 weeks ago
Is the only drug for restless leg syndrome to blame for patients' suicidal thoughts?

7 months, 1 week ago
Second Alzheimer’s drug expected to be blocked for NHS use

55 years, 3 months ago
The Uncertain Path Forward for Psychedelic Medicine

7 months, 3 weeks ago
FDA rejects psychedelic MDMA as treatment for PTSD, calling for additional study

7 months, 4 weeks ago
How the FDA could shape the future of psychedelics research

9 months, 1 week ago
Psychedelics’ Long Strange Trip to the Doctor’s Office

9 months, 3 weeks ago
Trouble for ecstasy? What MDMA’s FDA setback could mean for psychedelics

9 months, 3 weeks ago
Alzheimer’s drug that can slow disease gets backing from FDA advisers

10 months, 4 weeks ago
Bill could end holdup for California research on psychedelics and addiction treatment

11 months, 3 weeks ago
It’s the first drug shown to slow Alzheimer’s. Why is it off to a slow start?

1 year, 1 month ago
The rocky vista of medicinal cannabis research is bringing into view

1 year, 1 month ago
Use of innovative psychedelic treatments for mental health divides the experts

1 year, 2 months ago
As investors pile into psychedelics, idealism gives way to pharma economics

1 year, 2 months ago
Biogen will stop selling its controversial Alzheimer’s drug Aduhelm

1 year, 2 months ago
Australians with ADHD enduring months-long shortage of critical drug Vyvanse

1 year, 3 months ago